These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16313334)

  • 1. Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen.
    Resnick IB; Abdul Hai A; Shapira MY; Bitan M; Hershkovitz E; Schwartz A; Ben-Harush M; Or R; Slavin S; Kapelushnik J
    Clin Transplant; 2005 Dec; 19(6):840-7. PubMed ID: 16313334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful cord blood transplantation with reduced-intensity conditioning for childhood cerebral X-linked adrenoleukodystrophy at advanced and early stages.
    Niizuma H; Uematsu M; Sakamoto O; Uchiyama T; Horino S; Onuma M; Matsuhashi T; Rikiishi T; Sasahara Y; Minegishi M; Tsuchiya S
    Pediatr Transplant; 2012 Mar; 16(2):E63-70. PubMed ID: 21834803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
    Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy.
    Beam D; Poe MD; Provenzale JM; Szabolcs P; Martin PL; Prasad V; Parikh S; Driscoll T; Mukundan S; Kurtzberg J; Escolar ML
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):665-74. PubMed ID: 17531776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
    Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
    Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.
    Delgado J; Marco A; Moreno E; Piñana J; Valcarcel D; Martino R; Briones J; Sureda A; Brunet S; Sierra J
    Cytotherapy; 2009; 11(3):356-61. PubMed ID: 19148841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation.
    Wilken B; Dechent P; Brockmann K; Finsterbusch J; Baumann M; Ebell W; Korenke GC; Pouwels PJ; Hanefeld FA; Frahm J
    Neuropediatrics; 2003 Jun; 34(5):237-46. PubMed ID: 14598229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
    Bernardo ME; Zecca M; Piras E; Vacca A; Giorgiani G; Cugno C; Caocci G; Comoli P; Mastronuzzi A; Merli P; La Nasa G; Locatelli F
    Br J Haematol; 2008 Nov; 143(4):548-51. PubMed ID: 18986389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.
    Kornguth DG; Mahajan A; Woo S; Chan KW; Antolak J; Ha CS
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1140-4. PubMed ID: 17379444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.
    Komatsu T; Narimatsu H; Yoshimi A; Kurita N; Kusakabe M; Hori A; Murashige N; Matsumura T; Kobayashi K; Yuji K; Tanaka Y; Kami M
    Ann Hematol; 2007 Jan; 86(1):49-54. PubMed ID: 17036221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
    Krejci M; Mayer J; Doubek M; Brychtova Y; Pospisil Z; Racil Z; Dvorakova D; Lengerova M; Horky O; Koristek Z; Dolezal T; Vorlicek J
    Bone Marrow Transplant; 2006 Oct; 38(7):483-91. PubMed ID: 16980996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful allogeneic unrelated bone marrow transplantation using reduced-intensity conditioning for the treatment of X-linked adrenoleukodystrophy in a one-yr-old boy.
    Okamura K; Watanabe T; Onishi T; Watanabe H; Fujii E; Mori K; Matsuda J
    Pediatr Transplant; 2009 Feb; 13(1):130-3. PubMed ID: 18822105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
    Yabe M; Sako M; Yabe H; Osugi Y; Kurosawa H; Nara T; Tokuyama M; Adachi S; Kobayashi C; Yanagimachi M; Ohtsuka Y; Nakazawa Y; Ogawa C; Manabe A; Kojima S; Nakahata T;
    Pediatr Transplant; 2008 Dec; 12(8):862-7. PubMed ID: 18397212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.